Silexion CSO receives 6,000-share RSU grant

Silexion Therapeutics Corp reported that CSO and CDO Shirvan Mitchell received a grant of 6,000 Ordinary Shares via fully vested restricted share units, settled immediately in respect of his services as an officer and approved by the board of directors.

Rhea-AI Filing Summary

Silexion Therapeutics Corp reported that CSO and CDO Shirvan Mitchell received a grant of 6,000 Ordinary Shares via fully vested restricted share units, settled immediately in respect of his services as an officer and approved by the board of directors. Following this grant, he directly holds 8,789 Ordinary Shares.

The filing also updates option holdings after a 1-for-10 reverse share split effective on May 28, 2026. Mitchell now holds options to purchase 48 Ordinary Shares at an exercise price of $9,077.10 per share, expiring on June 7, 2032.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 2 txns

Insider Shirvan Mitchell

Role CSO and CDO

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	6,000	$0.00	$0.00
holding	Stock Option (right to buy Ordinary Shares)	--	--	--

Holdings After Transaction: Ordinary Shares — 8,789 shares (Direct); Stock Option (right to buy Ordinary Shares) — 48 contracts (Direct)

Footnotes (4)

1. F1. The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on March 30, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 27,889 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 2,789 ordinary shares, par value $0.135, prior to the grant reported in this Form 4).
2. F2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
3. F3. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
4. F4. The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 478 options to purchase 478 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person, as reported in that Form 4, to become 48 options to purchase 48 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share).

Key Figures

RSU grant shares: 6,000 Ordinary Shares Shares held after grant: 8,789 Ordinary Shares Reverse share split ratio: 1-for-10 +5 more

8 metrics

RSU grant shares 6,000 Ordinary Shares Fully vested RSUs settled into shares for officer services

Shares held after grant 8,789 Ordinary Shares Direct holdings following the 6,000-share grant

Reverse share split ratio 1-for-10 Reverse share split effective May 28, 2026

Pre-split shares 27,889 Ordinary Shares Became 2,789 Ordinary Shares after 1-for-10 split

Post-split option count 48 options for 48 shares Adjusted from 478 options after reverse split

Option exercise price $9,077.10 per share Exercise price for options expiring June 7, 2032

Option expiration date June 7, 2032 Expiration of stock options on Ordinary Shares

Post-split par value $0.135 per share Par value of Ordinary Shares after reverse split

Key Terms

reverse share split, restricted share units (RSUs), Stock Option (right to buy Ordinary Shares), exercise price, +1 more

5 terms

reverse share split financial

"reflects an adjustment ... due to the 1-for-10 reverse share split effected by the Issuer"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

restricted share units (RSUs) financial

"grant ... of fully vested restricted share units (RSUs), which were immediately settled"

Restricted share units (RSUs) are a form of employee pay where a company promises to give shares (or their cash value) to workers after certain conditions, usually time or performance, are met. For investors, RSUs matter because they can increase the number of shares outstanding and signal how management is being paid and incentivized—think of them as delayed bonuses that convert into ownership when vesting conditions are satisfied.

Stock Option (right to buy Ordinary Shares) financial

"security_title: Stock Option (right to buy Ordinary Shares)"

exercise price financial

"at an exercise price of $9,077.10 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Ordinary Shares financial

"Ordinary Shares, par value $0.135 per share ("ordinary shares")"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Silexion Therapeutics (SLXN) report for Shirvan Mitchell?

Silexion Therapeutics reported that CSO and CDO Shirvan Mitchell received a grant of 6,000 Ordinary Shares. These shares came from fully vested restricted share units settled immediately as compensation for his officer services and were approved by the company’s board of directors.

How many Silexion Therapeutics (SLXN) shares does Shirvan Mitchell hold after this Form 4?

After the reported transaction, Shirvan Mitchell directly holds 8,789 Ordinary Shares of Silexion Therapeutics. This total reflects both his existing holdings, adjusted for the reverse share split, and the 6,000-share RSU grant that was immediately settled into Ordinary Shares.

What did the reverse share split change for Silexion (SLXN) CSO Shirvan Mitchell?

A 1-for-10 reverse share split on May 28, 2026 reduced Mitchell’s reported 27,889 Ordinary Shares to 2,789 shares. It also adjusted 478 options at $907.71 into 48 options at an exercise price of $9,077.10 per share, maintaining economic value while changing share counts.

What stock options does Shirvan Mitchell hold in Silexion Therapeutics (SLXN) after the filing?

Mitchell holds options to purchase 48 Ordinary Shares of Silexion Therapeutics. These options carry an exercise price of $9,077.10 per share and expire on June 7, 2032, reflecting adjustments from the company’s 1-for-10 reverse share split completed in May 2026.

How was the 6,000-share grant to Silexion (SLXN) CSO structured?

The 6,000-share grant to Shirvan Mitchell was delivered as fully vested restricted share units. These RSUs were immediately settled into underlying Ordinary Shares, serving as compensation for his services as an officer and granted with approval from Silexion’s board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shirvan Mitchell

(Last) (First) (Middle)

C/O SILEXION THERAPEUTICS CORP

12 ABBA HILLEL ROAD

(Street)

RAMAT GAN 5250606

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSO and CDO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/04/2026		A(2)		6,000	A	$0	8,789	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Ordinary Shares)(3)	$9,077.1(4)							08/15/2024	06/07/2032	Ordinary Shares	48(4)		48(4)	D

Explanation of Responses:

1. The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on March 30, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 27,889 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 2,789 ordinary shares, par value $0.135, prior to the grant reported in this Form 4).

2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.

3. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

4. The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 478 options to purchase 478 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person, as reported in that Form 4, to become 48 options to purchase 48 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share).

	/s/ Mirit Horenshtein Hadar, Attorney-in-fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)